首页> 美国卫生研究院文献>Scientific Reports >Heart function and thoracic aorta gene expression profiling studies of ginseng combined with different herbal medicines in eNOS knockout mice
【2h】

Heart function and thoracic aorta gene expression profiling studies of ginseng combined with different herbal medicines in eNOS knockout mice

机译:人参联合不同草药对eNOS基因敲除小鼠心功能和胸主动脉基因表达谱的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ginseng, a popular herbal remedy, is often used in combination with other drugs to achieve the maximum therapeutic response. Shenfu (SFI) and Shenmai injection (SMI) have been widely used to treat cardiovascular disease in China. Our study explored the cardiovascular protection of SFI and SMI in eNOS knockout mice to investigate the differences and similarities of the two ginseng-combinations. Transthoracic echocardiography was performed to evaluate the left ventricular structure and function at baseline and 3, 7, and 14 days after drug administration. Agilent Gene Expression microarrays were used to demonstrate the gene expression profiling of the thoracic aorta. Ingenuity Pathway Analysis was performed to evaluate the mechanism improved by SFI and SMI in eNOS knockout mice. Both SFI and SMI could modulate Gadd45 Signaling from TOP15 canonical pathways. Moreover, SFI showed a better effect in the early treatment stage and improved myocardial function via GATA4, GATA6 and COL3A1. Meanwhile, SMI exerted better protective effects at the chronic stage, which may be related to endothelium protection by VEGFA and ACE. The advantage of multi-target by drug combination in progression of complex diseases should be noticed. The appropriate adjustment of drug combination could lead to a better accurate medical care in clinic.
机译:人参是一种流行的草药,经常与其他药物结合使用以达到最大的治疗效果。神甫(SFI)和神麦注射液(SMI)在中国已广泛用于治疗心血管疾病。我们的研究探索了eNOS基因敲除小鼠对SFI和SMI的心血管保护作用,以研究两种人参组合的异同。经胸超声心动图评估基线和给药后3、7和14天的左心室结构和功能。安捷伦基因表达微阵列用于证明胸主动脉的基因表达谱。进行了独创性途径分析以评估SNO和SMI在eNOS基因敲除小鼠中改善的机制。 SFI和SMI均可调节来自TOP15规范途径的Gadd45信号传导。此外,SFI在早期治疗中显示出更好的疗效,并通过GATA4,GATA6和COL3A1改善了心肌功能。同时,SMI在慢性期具有更好的保护作用,这可能与VEGFA和ACE对内皮的保护有关。应注意在复杂疾病的进展中通过药物组合实现多靶点的优势。药物组合的适当调整可导致临床上更好的准确医疗护理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号